目的 探究金荞麦胶囊联合沙美特罗替卡松粉吸入剂治疗支气管哮喘的临床疗效。方法 选取2016年5月—2018年5月在上海市金山区中西医结合医院接受治疗的140例支气管哮喘患者作为研究对象，按随机数字表分为对照组和治疗组，每组各70名。对照组患者吸入沙美特罗替卡松粉吸入剂，50 μg/250 μg，2次/d；治疗组在对照组治疗的基础上口服金荞麦胶囊，4粒/次，3次/d。两组患者均连续治疗3个月。观察两组患者的临床疗效，比较两组治疗前后的肺功能指标、圣乔治呼吸问卷评分和不良反应发生情况。结果 治疗后，对照组和治疗组的总有效率分别为77.14%、92.86%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者的第一秒用力呼气容积（FEV₁）和呼气峰流速（PEF）均明显升高，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组肺功能指标显著高于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者的呼吸症状、活动受限和疾病影响评分均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组呼吸症状、活动受限和疾病影响评分均显著低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗期间，治疗组不良反应发生率为4.29%，显著低于对照组的7.14%，两组不良反应发生率比较差异具有统计学意义（P<0.05）。结论 金荞麦胶囊联合沙美特罗替卡松粉吸入剂治疗支气管哮喘具有较好的临床疗效，能够改善患者肺功能指标和生活质量，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Jinqiaomai Capsules combined with Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation in treatment of bronchial asthma. Methods Patients (140 cases) with bronchial asthma in Shanghai Jinshan TCM Integrated Hospital from May 2016 to May 2018 were randomly divided into control and treatment groups, and each group had 70 cases. Patients in the control group were inhalation administered with Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation, 50 μg/250 μg, twice daily. Patients in the treatment group were po administered with Jinqiaomai Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 3 month. After treatment, the clinical efficacies were evaluated, and lung function indexes, the St. George's respiratory questionnaire scores, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 77.14% and 92.86%, respectively, and there were differences between two groups (P<0.05). After treatment, the FEV₁ and PEF levels in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, the lung function indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, the respiratory symptoms, activity limitation and disease impact scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the respiratory symptoms, activity limitation and disease impact scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). During the treatment, the incidence of adverse reactions in the treatment group was 4.29%, which was significantly lower than 7.14% in the control group, and there were differences between two groups (P<0.05). Conclusion Jinqiaomai Capsules combined with Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation has clinical curative effect in treatment of bronchial asthma, can improve the lung function indexes and quality of life of patients, which has a certain clinical application value.